Form 4: Cabaletta Bio Director Receives Stock Option Grant

Director Catherine Bollard was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Summary

• Director Catherine Bollard acquired 22,000 stock options in Cabaletta Bio, Inc. (CABA).
• The options have an exercise price of $3.22 per share.
• The grant is scheduled to vest in full on the earlier of June 9, 2027, or the date of the next annual stockholders' meeting.
• The options expire on June 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $3.22 may be subject to market fluctuations relative to the future share price.

Future Outlook

The options vest in one year, aligning the director's tenure with the company's upcoming annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain specialized scientific and clinical expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for small-cap biotechnology firms.
• The use of time-based vesting is standard for board-level equity incentives.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 9, 2027, or the next annual meeting.

Key Dates

Keywords

Cabaletta Bio, CABA, Director Compensation, Stock Options, Insider Transaction, Biotech